Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,569 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control regimen Clear all

Conditions: Multiple Sclerosis
Interventions: Isoxsuprine Hydrochloride, Placebo, Corticosteroid; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Osteoarthritis of the Knee or Hip
Interventions: Fasinumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 5,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 50
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 44 more

Conditions: Colitis, Ulcerative
Interventions: Guselkumab, Golimumab, JNJ-78934804, Placebo; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 63
States / cities: Arcadia, California • Coronado, California • Lancaster, California + 54 more

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions: Bimekizumab, Secukinumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 25
States / cities: Santa Ana, California • Danbury, Connecticut • Ocala, Florida + 20 more

Conditions: Hypertension, Pregnancy-Induced
Interventions: Acetaminophen, Ibuprofen; Drug
Lead sponsor: MemorialCare Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Psoriasis
Interventions: Vehicle (Placebo) applied BID, QRX-101 75 mcg/g ointment applied QD, QRX-101 75 mcg/g ointment applied BID; Drug
Lead sponsor: QuatRx Pharmaceuticals Company; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 12
States / cities: Hot Springs, Arkansas • Santa Rosa, California • Overland Park, Kansas + 9 more

Conditions: Sarcopenia
Interventions: REGN1033 (SAR391786), placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 70 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 33
States / cities: Anniston, Alabama • Phoenix, Arizona • El Cajon, California + 30 more

Conditions: Improve Photoaging Signs
Interventions: CE Ferulic, Sham Comparator, 1927nm (Clear and Brilliant Perméa®); Drug · Device
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 30 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Migraine
Interventions: Nasal CO2, Inactive Placebo; Drug
Lead sponsor: Capnia, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 15
States / cities: Birmingham, Alabama • Stanford, California • East Hartford, Connecticut + 12 more

Conditions: Chemotherapy-induced Peripheral Neuropathy, Taxane-Induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions: Paxman Limb Cryocompression System; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Vasomotor Symptoms, Hot Flashes
Interventions: RAD1901, Placebo; Drug · Other
Lead sponsor: Radius Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk, Diabetes, Gestational
Interventions: Sliding Scale Insulin, Up-Titration of Home Insulin, Continuous Insulin Infusion, Dexcom G6 Professional Continuous Glucose Monitor; Drug · Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Up to 50 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Birmingham, Alabama • Portland, Oregon • Greenville, South Carolina + 1 more

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions: Remote monitoring; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more

Conditions: Adenotonsillectomy, Postoperative Pain
Interventions: Celecoxib, Acetaminophen, Dexamethasone; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 2 Years to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin aspart, insulin detemir; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 33
States / cities: Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 28 more

Conditions: Cystic Fibrosis, Quality of Life
Interventions: Massage Therapy; Procedure
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years to 21 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Essential Tremor
Interventions: 100 mg PRAX-944, 60 mg PRAX-944, Placebo, Flexibly dosed 20 mg to 100 mg PRAX-944; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 31 more

Conditions: HIV-1-infection, Elevated Cardiovascular Risk
Interventions: CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 45 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 19
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 14 more

Conditions: Medication Adherence, Transplant; Kidney
Interventions: mHealth Intervention; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 22 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Von Willebrand Disease
Interventions: VWF/FVIII products; Drug
Lead sponsor: Skane University Hospital; Other
Eligibility: Not listed
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Milwaukee, Wisconsin

Conditions: Anesthesia, Local, Phrenic Nerve Paralysis, Upper Extremity Injury, Phrenic Nerve Palsy on the Left, Phrenic Nerve Palsy on the Right
Interventions: Normal saline injected via interscalene nerve catheter, Placebo; Procedure · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Multiple Sclerosis, Hypertension
Interventions: Home-based aerobic training; Behavioral
Lead sponsor: University of Massachusetts, Boston; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Keloid
Interventions: Apligraf, Standard dressing regimen; Device · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Miami Beach, Florida

Conditions: Postpartum Complication, Maternal Hypertension, High Blood Pressure
Interventions: Oral Nifedipine, Oral Labetalol; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Loma Linda, California

Search by objective public record fields.

Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Hypertension In Postpartum Preeclampsia Study

Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

Skin Care Regimen for Improving Photoaging Signs on the Face

The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines

Cryocompression for CIPN

Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes

A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy

Preoperative Celecoxib and Acetaminophen Versus Acetaminophen Alone for Pain Control After Pediatric Adenotonsillectomy

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen

The Effects of Massage Therapy on QOL in Youth/Young Adults With Cystic Fibrosis

A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor

A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Kidney Transplant Recipients

The Von Willebrand Disease (VWD) International Prophylaxis Study

Interscalene Brachial Plexus Block Washout to Reverse Inadvertent Phrenic Nerve Blockade

Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension

A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids

Safest Choice of Antihypertensive Regimen for Postpartum Hypertension